314 related articles for article (PubMed ID: 18089874)
1. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
Bottomley A; Coens C; Efficace F; Gaafar R; Manegold C; Burgers S; Vincent M; Legrand C; van Meerbeeck JP;
J Clin Oncol; 2007 Dec; 25(36):5770-6. PubMed ID: 18089874
[TBL] [Abstract][Full Text] [Related]
2. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
Bottomley A; Gaafar R; Manegold C; Burgers S; Coens C; Legrand C; Vincent M; Giaccone G; Van Meerbeeck J; ;
J Clin Oncol; 2006 Mar; 24(9):1435-42. PubMed ID: 16446322
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
van Meerbeeck JP; Gaafar R; Manegold C; Van Klaveren RJ; Van Marck EA; Vincent M; Legrand C; Bottomley A; Debruyne C; Giaccone G; ;
J Clin Oncol; 2005 Oct; 23(28):6881-9. PubMed ID: 16192580
[TBL] [Abstract][Full Text] [Related]
4. Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer.
Efficace F; Innominato PF; Bjarnason G; Coens C; Humblet Y; Tumolo S; Genet D; Tampellini M; Bottomley A; Garufi C; Focan C; Giacchetti S; Lévi F;
J Clin Oncol; 2008 Apr; 26(12):2020-6. PubMed ID: 18421055
[TBL] [Abstract][Full Text] [Related]
5. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed in malignant pleural mesothelioma.
Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
[TBL] [Abstract][Full Text] [Related]
7. [Long-term prognostic analysis of patients with malignant pleural mesothelioma].
Cao KJ; Cui NJ
Ai Zheng; 2005 Jan; 24(1):72-5. PubMed ID: 15642204
[TBL] [Abstract][Full Text] [Related]
8. Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.
Woods B; Paracha N; Scott DA; Thatcher N
Lung Cancer; 2012 Feb; 75(2):261-7. PubMed ID: 21937141
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study.
Mauer ME; Taphoorn MJ; Bottomley A; Coens C; Efficace F; Sanson M; Brandes AA; van der Rijt CC; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; van den Bent MJ;
J Clin Oncol; 2007 Dec; 25(36):5731-7. PubMed ID: 18089867
[TBL] [Abstract][Full Text] [Related]
10. Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?
Efficace F; Bottomley A; Coens C; Van Steen K; Conroy T; Schöffski P; Schmoll H; Van Cutsem E; Köhne CH
Eur J Cancer; 2006 Jan; 42(1):42-9. PubMed ID: 16298522
[TBL] [Abstract][Full Text] [Related]
11. A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.
Berghmans T; Lafitte JJ; Paesmans M; Stach B; Berchier MC; Wackenier P; Lecomte J; Collon T; Mommen P; Sculier JP;
Lung Cancer; 2005 Oct; 50(1):75-82. PubMed ID: 16005104
[TBL] [Abstract][Full Text] [Related]
12. Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.
Efficace F; Biganzoli L; Piccart M; Coens C; Van Steen K; Cufer T; Coleman RE; Calvert HA; Gamucci T; Twelves C; Fargeot P; Bottomley A;
Eur J Cancer; 2004 May; 40(7):1021-30. PubMed ID: 15093577
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study.
Efficace F; Therasse P; Piccart MJ; Coens C; van Steen K; Welnicka-Jaskiewicz M; Cufer T; Dyczka J; Lichinitser M; Shepherd L; de Haes H; Sprangers MA; Bottomley A
J Clin Oncol; 2004 Aug; 22(16):3381-8. PubMed ID: 15310784
[TBL] [Abstract][Full Text] [Related]
14. Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation.
Hollen PJ; Gralla RJ; Liepa AM; Symanowski JT; Rusthoven JJ
Cancer; 2004 Aug; 101(3):587-95. PubMed ID: 15274072
[TBL] [Abstract][Full Text] [Related]
15. [Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
Reck M; Heigener DF; Gatzemeier U
Zentralbl Chir; 2008 Jun; 133(3):238-42. PubMed ID: 18563688
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
Jassem J; Ramlau R; Santoro A; Schuette W; Chemaissani A; Hong S; Blatter J; Adachi S; Hanauske A; Manegold C
J Clin Oncol; 2008 Apr; 26(10):1698-704. PubMed ID: 18375898
[TBL] [Abstract][Full Text] [Related]
17. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
Borasio P; Berruti A; Billé A; Lausi P; Levra MG; Giardino R; Ardissone F
Eur J Cardiothorac Surg; 2008 Feb; 33(2):307-13. PubMed ID: 18164622
[TBL] [Abstract][Full Text] [Related]
18. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.
Richards WG; Zellos L; Bueno R; Jaklitsch MT; Jänne PA; Chirieac LR; Yeap BY; Dekkers RJ; Hartigan PM; Capalbo L; Sugarbaker DJ
J Clin Oncol; 2006 Apr; 24(10):1561-7. PubMed ID: 16575008
[TBL] [Abstract][Full Text] [Related]
19. Raltitrexed in mesothelioma.
Surmont VF; van Meerbeeck JP
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1481-90. PubMed ID: 21999120
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
Nakagawa K; Yamazaki K; Kunitoh H; Hida T; Gemba K; Shinkai T; Ichinose Y; Adachi S; Nambu Y; Saijo N; Fukuoka M
Jpn J Clin Oncol; 2008 May; 38(5):339-46. PubMed ID: 18434338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
